Cancerous inhibitor of protein phosphatase 2A enhances chemoresistance of gastric cancer cells to oxaliplatin

Figure 5 Downregulation of cancerous inhibitor of protein phosphatase 2A significantly increased sensitivity to oxaliplatin in human gastric cancer cells. A: MKN-45 cells were transfected with cancerous inhibitor of protein phosphatase 2A (CIP2A) small interfering RNA (siRNA) for 48 h and were added with oxaliplatin at different concentrations for 24 h; B: AGS cells were transfected with cancerous inhibitor of protein phosphatase 2A siRNA for 48 h and were added with oxaliplatin at different concentrations for 24 h. The cell viability was examined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tetrazolium assay. The results consisted of three independent tests. The siRNA group vs the control siRNA group. ^bP < 0.01.